Services
Antipsychotic Medications
Program to Monitor and Improve Appropriate Use of Antipsychotic Medications
Consistent with the Centers for Medicare and Medicaid services (CMS) national goal of reducing the use of anti-psychotic medications with nursing home residents for off-label use.
PROVIDER would support the Facility in proactively collecting, analyzing, tracking and trending your medication data to identify opportunities for improvement and to objectively demonstrate progress and success. Critical data points should include:
- PROVIDER would support the Facility in proactively collecting, analyzing, tracking and trending your medication data to identify opportunities for improvement and to objectively demonstrate progress and success. Critical data points should include:
- Objective measures to support resident’s response to reductions.
PROVIDER will establish better disease state diagnosis upon evaluation to better identify other underlying medical conditions that may manifest psychiatric symptoms. Often these medical conditions can be treated with FDA approved medications and behavioral symptoms can be minimized or eliminated.
PROVIDER Nurse Practitioner will participate in the Behavioral Management Committee meetings and conduct GDR and AIMS testing on a regular schedule. This will assist in ensuring that sufficient documentation is provided to justify the use of the medication including diagnosis, failed alternative options, regular review and documentation of why it is contraindicated to withdraw such medications and any objective data available in the medical record to support the efficacy of the medication.
Diagnoses can be reviewed to ensure they are consistent with the medication being used. This is critical as the new CMS initiative does not penalize facilities for use of antipsychotic medications if the resident presents with Schizophrenia, Bipolar Disorder, Huntington’s Disease, Tourette’s Syndrome or active psychosis.
